echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Generics don't make money, innovation track is crowded... Where is the way for domestic pharmaceutical enterprises to transform?

    Generics don't make money, innovation track is crowded... Where is the way for domestic pharmaceutical enterprises to transform?

    • Last Update: 2019-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Generics don't make money and the innovation track is crowded The Chinese pharmaceutical industry is facing a comprehensive transformation and upgrading This is a strategic issue that domestic pharmaceutical companies have to consider and measure at present, especially under the influence of 4 + 7 and medical insurance control policy 4 + 7 triggered the industry tsunami a number of generic drugs are being eliminated! In September of this year, the second season of 4 + 7 volume purchase is staged Among the results of the expansion, atorvastatin decreased the most, 78.18% on the basis of the 4 + 7 bid price; amlodipine decreased 60% compared with the 4 + 7 bid price last year Compared with the lowest purchase price in 2018 in the alliance region, the average price to be selected will be reduced by 59% Industry insiders revealed that, no surprise, at the end of this year, 4 + 7 will start to explore the expansion of varieties, which will have a greater impact on the whole industry 4 + 7 is speeding up the reshuffle of generic pharmaceutical industry, and leading pharmaceutical enterprises have quietly started their own transformation and upgrading At the 2019 China Pharmaceutical entrepreneur scientist investor conference, LV Mingfang, managing director of Fangyuan capital, mentioned that Hengrui pharmaceutical had suspended the research and development of some uncompetitive generic projects last year, and only made innovative drugs and high-end generic drugs with core value Sun piaoyang, chairman of Hengrui pharmaceutical, also responded, saying that this is because the approval of generic drugs is more and faster at present, and the access after listing is slower And the varieties close to the patent period have been basically imitated in the past few years, and the value of the remaining varieties on the market is not high Based on the measurement of input and output, Hengrui has stopped a number of generic drug development projects Talking about the impact of 4 + 7 on the whole industry, Lu said that the long-term price of generic drugs in the future must be fast downward In addition, the rare is the most important thing, so the enterprises need to change their own survival and development situation to become a more competitive enterprise According to Ren Jinsheng, chairman of Xiansheng pharmaceutical, more than 4000 pharmaceutical factories in China are basically R & D of generic drugs, a small part of which is the combination of generic drugs and innovative drugs In his opinion, in the next 10 years, more than 4000 may be reduced to 1000 or even less, and the speed depends on the policy The price will fall or the coverage will expand on the basis of the present In the future, innovative drugs will be able to be really large-scale, Pharmaceutical enterprises should concentrate their resources on the research and development of innovative drugs However, a phenomenon can not be ignored: the generic track is crowded, and the real situation is that the innovative track is also crowded Yu Mingde, honorary president of China Pharmaceutical Enterprise Management Association, introduced the current situation of the transformation of China's pharmaceutical industry, noting that there is too much convergence in drug research and development in China's pharmaceutical industry Take the hot PD-1, which has been approved by three companies, and there are more than 30 companies waiting in line Yu Mingde pointed out that too much convergence research and development will waste human, material and financial resources, which is worthy of attention In addition, there is also a huge risk that the capital market overvalues new drugs, listed companies or companies to be listed According to the data, there are more than 100 enterprises known to be still researching PD - (L) 1 products in China, including Fuhong Hanlin, Baiji Shenzhou and other famous innovative pharmaceutical enterprises In the next two years, it is expected that more than 10 PD - (L) 1 antibodies will be approved or applied for listing for the first time in China The layout of individual indications is very crowded, such as NSCLC, Hodgkin's lymphoma, etc Moreover, the innovative track is much narrower than the generic track Innovation requires the development of "new drugs"? Combined with the current pharmaceutical environment, some business leaders believe that we should relax our understanding of innovation, for example, it is also an innovation to pass the consistency evaluation in the first three companies; the upgrading of sales and the improvement of the network on the road of innovation, including the innovation of generic drugs themselves, is also an innovation As Ding Zhao, chairman of Sichuan Huiyu Pharmaceutical Co., Ltd., said, innovation is an inevitable trend, and the key to competition is internal power Who can make it faster is the same as making generic drugs How to improve the internal power of enterprises in all aspects is more important than choosing a race track Many practitioners believe that policies such as 4 + 7 and medical insurance fee control are driving the return of the value of the pharmaceutical industry, which is also in line with the law of market economy In the short term, the challenges to small and medium-sized enterprises are huge, but they are still good for leading enterprises The scattered pattern in the past will be changed, and the business environment will be better in the future.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.